PARPis significantly extended PFS with underlying BRCA1/2 mutation in the germline and tumor (somatic) compared to BRCA1/2-negative HGSOC [14,37], so patients with HGSOC benefit from BRCA1/2 mutation and HRD positivity [14,31]. Here, BRCA1 is linked to neoplasm.